RGRX - Regenerx Biopharmaceuticals Inc Profile, Share Price, Market Analysis, Charts, Fundamentals

Company Name, Ticker, Suppliers, else..

Talaris Therapeutics Inc announced operating shortfall of $-19.825 millions, in the most recent fiscal period

The stockholders have not hoped for any adjustments at the revenue during the the earnings season of the October to December 31 2022 at the Talaris Therapeutics Inc . Yet, they consider the Biotechnology & Pharmaceuticals company's operating shortfall which has been at $-19.825 millions, in the same period.

The company reported that Sales have truly advanced, amid the fiscal fourth quarter of 2022

For the fourth quarter of 2022 Inhibikase Therapeutics Inc decreased a loss per share of $-0.17 per share compare to $-0.20 a year ago and EPS improved from $-0.18 per share from the prior reporting season.

Sales grew sharply to $0.06 millions from $0.00 millions in the similar reporting season a year ago and sequentially Sales doubled by 771.842 % from $0.01 millions.

Scynexis Inc reported exceptional results, amid the October to December 31 2022 interval

For the most recent fiscal period SCYX decreased a loss per share of $-0.22 per share compare to $-1.08 a year ago and earnings per share improved from $-0.62 per share from the preceding reporting period.

Sales increased sharply by 155.276 % to $1.52 millions from $0.60 millions in the comparable reporting period a year ago and sequentially Sales decreased by -2.119 % from $1.56 millions.

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071

RGRX Company Profile

Talaris Therapeutics Inc announced operating shortfall of $-19.825 millions, in the most recent fiscal period

The company reported that Sales have truly advanced, amid the fiscal fourth quarter of 2022

Scynexis Inc reported exceptional results, amid the October to December 31 2022 interval

Business expenditures were increasing at the IRON in the financial fourth quarter of 2022

The Deficit has expanded at the Miscellaneous Financial Services company all along the financial time-frame closing December 31 2022


Economy Advance Monthly Sales Consumer Price Index CPI Producer Price Index PPI Retail Inventories Personal Income Gross Domestic Product GDP Money Supply Industrial Production Productivity Employment Situation US International Trade Factory Orders Durable Goods Construction Spending Housing Starts Vehicle Unit Sales	Stocks Event Calendar PLCE's Profile Stock Price PLCE's Financials Business Description Fundamentals Charts & Quotes PLCE's News Suppliers PLCE's Competitors Customers & Markets Economic Indicators PLCE's Growth Company Segments	Screening Stock Performance Growth Rates Profitability Valuation Dividend Financial Strength Efficiency Largest Companies Management Effectivness